If you're leading an accounting firm in early 2026, you feel the pressure. Every conference promises AI will transform the profession. Every vendor has a new automation story. Every article warns that ...

Advisors know it intuitively: all stocks are not created equal, even those that look very similar on the surface. Yet, figuring out which to hold out of an ever-expanding assortment is a challenge.

New Peptide MAM (multi-attribute method) workflow for the BioAccord LC-MS System monitors product quality attributes that can affect efficacy and safety of innovator drugs and biosimilars. End-to-end ...